Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Disparities

Topic: Risk, prevention and care in population studies

Plain-language summary

A significant reduction in underdiagnosis of dementia was observed between the two periods, consistent across most countries. Progress in diagnosis was modified by country-level factors such as number of psychiatrists, formal long-term care worker at home or institutions, and positron emission tomography and individual-level factors including age, education, retirement status, nursing home residency, multimorbidity, and healthcare utilization patterns. The decreasing trend in underdiagnosis highlights the importance of targeted interventions including investment in psychiatric care services. Understanding remaining disparities is crucial for informing health policies and addressing inequalities to dementia diagnosis and care.

What this study adds

Evidence grade: Low

The record lists 10,402 participants. Across 19 European countries, underdiagnosis of dementia decreased between two periods, with progress linked to factors such as numbers of psychiatrists and use of PET. This is about improving detection and diagnosis, not about treating or preventing the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yu, J., Wang, P., Xie, S., Amin, J. K., Mueller, C. S., Hou, X., et al. (2025). Prevalence and progress of underdiagnosis of probable dementia: a repeated cross-sectional study in 19 European countries. BMC Medicine. https://doi.org/10.1186/s12916-025-04196-7

Vancouver

Yu J, Wang P, Xie S, Amin JK, Mueller CS, Hou X, et al. Prevalence and progress of underdiagnosis of probable dementia: a repeated cross-sectional study in 19 European countries. BMC Medicine. 2025. doi:10.1186/s12916-025-04196-7. PMID: 40597117.

BibTeX

@article{yu2025-40597117,
  author  = {Yu, Jiazhou and Wang, Pengyun and Xie, Shuyun and Amin, Jay K and Mueller, Christoph S. and Hou, Xiaohui and Chen, Xi and Underwood, Benjamin R. and others},
  title   = {{Prevalence and progress of underdiagnosis of probable dementia: a repeated cross-sectional study in 19 European countries}},
  journal = {BMC Medicine},
  year    = {2025},
  doi     = {10.1186/s12916-025-04196-7},
  pmid    = {40597117},
  url     = {https://doi.org/10.1186/s12916-025-04196-7}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Across 19 European countries, underdiagnosis of dementia decreased between two periods, with progress linked to factors such as numbers of psychiatrists and use of PET. This is about improving detection and diagnosis, not about treating or preventing the disease.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (BMC Medicine)
Journal's citation record 3 / 4 BMC Medicine: journal h-index 259 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 10,402 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 11 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.7 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 7.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Shanquan Chen: h-index 28 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Oxford: institution h-index 2,205 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40597117)
Free to read 2 / 2 Free to read
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disparities from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →